ECL
NYSE · USDOne year, rebased to 100
ECL SPY XLB (sector ETF) · weekly closesScore DNA
Each bar is a 0-100 score within the scored universeFlags
Smart-money strip
Each disclosure source on its own window. Filings coinciding is not coordination.Key financials · FY2025
USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.Valuation
ECL vs industry median
207 companies in Chemicals - SpecialtyEarnings delivery
Next report 2026-10-27 · consensus EPS $2.17Peers
Market-cap band, not the industry cohort above| Company | Mkt cap | P/E | ROE | Net margin | Rev growth | 12m return |
|---|---|---|---|---|---|---|
| ECL Ecolab Inc. | $81.0B | 38.5x | 21.4% | 12.6% | +2.2% | +7.0% |
| SHW The Sherwin-Williams Company | $81.4B | 30.6x | 65.1% | 12.4% | +5.8% | +1.3% |
| APD Air Products and Chemicals, | $66.7B | n/m | -0.3% | -45.6% | +4.5% | +18.3% |
| LIN Linde plc | $229.8B | 32.0x | 18.8% | 20.8% | +6.6% | +12.6% |
| PPG PPG Industries, Inc. | $23.9B | 15.3x | 19.6% | 9.7% | +12.3% | +7.1% |
| IFF International Flavors & Frag | $23.1B | 83.2x | 2.0% | 2.6% | −11.7% | — |
| LYB LyondellBasell Industries N. | $20.7B | n/m | -3.1% | 6.1% | −11.3% | — |
| SQM Sociedad QuÃmica y Minera d | $17.2B | 12.5x | 23.9% | 26.7% | +59.3% | — |
Recent 8-K filings
Context
Full factsheet
The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Narrow).
Read it in the browser Download (PDF)All fundamentals · 140 measures in 13 categories
Percentile = where ECL sits among 43 scored companies in Chemicals - Specialty (0 = lowest value, 100 = highest). It is a position, not a grade.Valuation
| Measure | ECL | Industry percentile |
|---|---|---|
| P/E (TTM) | 38.3x | 76th |
| PEG (P/E ÷ 3-yr EPS CAGR) | 1.73 | 29th |
| Price / sales | 4.8x | 88th |
| Price / book | 8.1x | 92nd |
| Price / tangible book | — | |
| Price / free cash flow | 43.2x | 89th |
| Price / operating cash flow | 26.5x | 90th |
| Enterprise value | $89.6B | 95th |
| EV / sales | 5.3x | 90th |
| EV / EBITDA | 24.9x | 89th |
| EV / EBIT | 31.1x | 80th |
| EV / free cash flow | 47.8x | 78th |
| Earnings yield | 2.6% | 55th |
| FCF yield | 2.3% | 24th |
| Operating cash flow yield | 3.8% | 14th |
| Graham number (per share) | $77.35 | 84th |
Profitability (TTM)
| Measure | ECL | Industry percentile |
|---|---|---|
| Gross margin | 44.1% | 90th |
| EBITDA margin | 21.4% | 88th |
| Operating margin | 17.4% | 85th |
| EBIT margin | 17.1% | 85th |
| Net margin | 12.6% | 88th |
| NOPAT margin | 14.1% | 83rd |
| FCF margin | 11.1% | 71st |
| Operating cash flow margin | 18.1% | 76th |
| R&D / revenue | 0.0% | 0th |
| SG&A / revenue | 26.0% | 85th |
| Stock comp / revenue | 0.8% | 73rd |
| Effective tax rate | 18.9% | 12th |
Returns on capital
| Measure | ECL | Industry percentile |
|---|---|---|
| ROE (on average equity) | 21.8% | 88th |
| ROA | 7.9% | 79th |
| ROIC | 12.7% | 79th |
| ROCE | 12.0% | 74th |
| Return on tangible assets | 10.7% | 76th |
| Cash ROIC (OCF / invested capital) | 16.4% | 69th |
| Gross profitability (GP / assets) | 24.8% | 81st |
| ROIC, 3-yr average | 13.1% | 90th |
| ROIC, 5-yr average | 14.0% | 85th |
| ROE, 5-yr average | 19.2% | 84th |
| Incremental ROIC | 11.6% | 55th |
Growth
| Measure | ECL | Industry percentile |
|---|---|---|
| Revenue growth (TTM YoY) | 7.1% | 63rd |
| Revenue growth (QoQ) | 8.6% | 31st |
| Revenue CAGR, 3 yr | 4.5% | 77th |
| Revenue CAGR, 5 yr | 6.8% | 68th |
| Gross profit CAGR, 3 yr | 9.3% | 85th |
| Operating income CAGR, 3 yr | 16.1% | 82nd |
| Net income growth (TTM YoY) | -0.9% | 33rd |
| Net income CAGR, 3 yr | 21.7% | 91st |
| EPS growth (TTM YoY) | -0.0% | 33rd |
| EPS CAGR, 3 yr | 22.2% | 91st |
| EPS CAGR, 5 yr | 15.5% | 83rd |
| FCF growth (TTM YoY) | 19.1% | 56th |
| FCF CAGR, 3 yr | 12.2% | 64th |
| Operating cash flow CAGR, 3 yr | 13.9% | 74th |
| Book value CAGR, 3 yr | 10.4% | 77th |
| Dividend CAGR, 3 yr | 4.7% | 84th |
| Sustainable growth rate | 13.6% | 68th |
Margin history & stability
| Measure | ECL | Industry percentile |
|---|---|---|
| Gross margin, 3-yr average | 43.6% | 92nd |
| Operating margin, 3-yr average | 16.7% | 85th |
| Net margin, 3-yr average | 12.4% | 90th |
| FCF margin, 3-yr average | 11.5% | 85th |
| Revenue stability (0-1) | 0.94 | 90th |
| Earnings stability (0-1) | 0.90 | 90th |
| Margin stability (0-1) | 0.95 | 78th |
Liquidity (latest quarter)
| Measure | ECL | Industry percentile |
|---|---|---|
| Cash & short-term investments | $5.1B | 100th |
| Net cash (− = net debt) | −$8.6B | 10th |
| Working capital | $5.0B | 100th |
| Current ratio | 1.84 | 50th |
| Quick ratio | 1.57 | 69th |
| Cash ratio (cash + ST investments / current liabilities) | 0.86 | 83rd |
| Defensive interval (days) | 696 days | 61st |
Leverage & solvency (latest quarter)
| Measure | ECL | Industry percentile |
|---|---|---|
| Total debt | $13.8B | 90th |
| Debt / equity | 1.37 | 82nd |
| Net debt / equity | 0.86 | 70th |
| Debt / assets | 46.0% | 79th |
| Debt / capital | 57.8% | 82nd |
| Debt / EBITDA | 3.82 | 57th |
| Net debt / EBITDA | 2.39 | 34th |
| Interest coverage (EBIT / interest) | 9.5x | 78th |
| Cash interest coverage | 10.1x | 78th |
| Debt payback (years of OCF) | 4.5 yrs | 52nd |
| Liabilities / assets | 66.3% | 71st |
| IS credit model rating | A | |
| Implied credit spread (bps) | 150 | 21st |
Efficiency
| Measure | ECL | Industry percentile |
|---|---|---|
| Asset turnover | 0.63 | 40th |
| Fixed asset turnover | 3.24 | 69th |
| Inventory turnover | 5.9 | 71st |
| Receivables turnover | 5.2 | 24th |
| Days sales outstanding | 71 days | 76th |
| Days inventory outstanding | 62 days | 29th |
| Days payables outstanding | 78 days | 83rd |
| Cash conversion cycle (days) | 55 days | 31st |
| Capex / revenue | 7.0% | 71st |
| Capex / depreciation | 1.63 | 88th |
| Operating expense ratio | 26.9% | 76th |
Cash flow & earnings quality
| Measure | ECL | Industry percentile |
|---|---|---|
| Operating cash flow / net income | 1.44 | 48th |
| FCF / net income | 0.89 | 28th |
| FCF / operating cash flow | 61.3% | 51st |
| Capex / operating cash flow | 38.7% | 49th |
| Accruals ratio | -3.5% | 74th |
| Sloan accruals ratio | 8.0% | 95th |
| Earnings quality score (0-1) | 1.00 | 40th |
Scores & forensic checks
| Measure | ECL | Industry percentile |
|---|---|---|
| IS score | 58 | 74th |
| IS profitability | 59 | 88th |
| IS growth | 45 | 39th |
| IS value | 37 | 21st |
| IS momentum | 74 | 63rd |
| IS risk (safety) | 100 | 79th |
| IS quality | 68 | 69th |
| IS balance sheet | 64 | 79th |
| IS earnings quality | 72 | 67th |
| IS cash flow | 60 | 76th |
| Piotroski F-score (0-9) | 5 | 29th |
| Altman Z-score | 4.1 | 81st |
| Beneish M-score | −2.52 | 73rd |
| Ohlson O-score | −7.79 | 36th |
| IS credit score | 74 | 76th |
Size (TTM)
| Measure | ECL | Industry percentile |
|---|---|---|
| Market cap | $81.0B | 95th |
| Revenue | $16.8B | 93rd |
| EBITDA | $3.6B | 93rd |
| Net income | $2.1B | 95th |
| Free cash flow | $1.9B | 88th |
| Total assets | $29.9B | 93rd |
| Shareholders' equity | $10.1B | 88th |
| Employees | 48,000 | 95th |
Insider transactions, last 6 months
Form 4 · most recent 12| Date | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-30 | Ballard Shari L Director |
Award / grant | 131 | — | — | 9,842 |
| 2026-09-30 | Ballard Shari L Director |
Award / grant | 131 | $276.36 | $36,252 | 9,973 |
| 2026-09-30 | Althoff Judson Director |
Award / grant | 131 | — | — | 1,407 |
| 2026-09-30 | Mckibben Tracy B Director |
Award / grant | 131 | — | — | 11,821 |
| 2026-09-30 | Maclennan David Director |
Award / grant | 131 | — | — | 25,579 |
| 2026-09-30 | Maclennan David Director |
Award / grant | 46 | $276.36 | $12,812 | 25,625 |
| 2026-09-30 | Larson Michael Director |
Award / grant | 131 | — | — | 19,326 |
| 2026-09-30 | Gross Marion K. Director |
Award / grant | 131 | — | — | 730 |
| 2026-09-30 | Green Eric Mark Director |
Award / grant | 131 | — | — | 8,089 |
| 2026-09-30 | Green Eric Mark Director |
Award / grant | 145 | $276.36 | $40,002 | 8,234 |
| 2026-09-30 | Doukeris Michel D Director |
Award / grant | 131 | — | — | 8,590 |
| 2026-09-30 | Zillmer John J Director |
Award / grant | 131 | — | — | 49,540 |
Shares acquired vs disposed, by month
acquired disposed · all Form 4 typesBy transaction type, 6 months
| Type | Direction | Filings | Shares | Value |
|---|---|---|---|---|
| Award / grant | Acquired | 43 | 13,099 | $2.5M |
| Open-market buy | Acquired | 6 | 14,240 | $3.7M |
| Open-market sale | Disposed | 5 | 36,790 | $10.1M |
| Option exercise | Disposed | 5 | 30,825 | $1.9M |
| Option exercise | Acquired | 5 | 30,825 | $1.9M |
| Tax withholding | Disposed | 3 | 7,769 | $2.1M |
| — | Disposed | 4 | 5,248 | $617,584 |
Form 144 notices
12 months: 15 notices · 105,489 shares · $29.9M| Filed | Filer | Shares proposed | Est. proceeds |
|---|---|---|---|
| 2026-08-18 | Christophe Beck | 17,862 | $4.9M |
| 2026-08-11 | Cook Gregory B | 4,567 | $1.3M |
| 2026-08-07 | Bradway Jennifer J. | 1,765 | $500,307 |
| 2026-07-30 | Kirkland Scott D. | 3,357 | $952,381 |
Congress trades
12 months: House 7 trades (4 purchases) · Senate 3 (0 purchases)| Traded | Member | Chamber | Type | Amount | Disclosed |
|---|---|---|---|---|---|
| 2026-09-25 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-10-09 |
| 2026-09-11 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-10-09 |
| 2026-05-15 | John Boozman | Senate | Sale | $1,001 - $15,000 | 2026-06-16 |
| 2026-05-15 | John Boozman | Senate | Sale (Partial) | $1,001 - $15,000 | 2026-06-15 |
| 2026-05-15 | John Boozman | Senate | Sale (Partial) | $1,001 - $15,000 | 2026-06-15 |
| 2026-05-01 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-06-11 |
| 2026-04-13 | Ro Khanna | House | Purchase | $1,001 - $15,000 | 2026-05-13 |
| 2025-02-26 | John Boozman | Senate | Purchase | $1,001 - $15,000 | 2025-03-06 |
Largest 13F holders
Quarter to 2026-06-30, the latest most managers have filed| Manager | Shares | Value | % of shares out |
|---|---|---|---|
| BlackRock, Inc. | 23,051,363 | $6.4B | 8.22% |
| VANGUARD CAPITAL MANAGEMENT LLC | 16,537,270 | $4.6B | 5.90% |
| STATE STREET CORP | 11,770,714 | $3.3B | 4.20% |
| JPMORGAN CHASE & CO | 11,330,314 | $3.2B | 4.04% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 6,300,975 | $1.8B | 2.25% |
| GEODE CAPITAL MANAGEMENT, LLC | 5,996,032 | $1.7B | 2.14% |
| MORGAN STANLEY | 4,909,345 | $1.4B | 1.75% |
| ROYAL BANK OF CANADA | 3,611,647 | $1.0B | 1.29% |
| Aristotle Capital Management, LLC | 3,516,811 | $979.8M | 1.25% |
| NORGES BANK | 3,350,825 | $933.6M | 1.20% |
| Capital Research Global Investors | 2,863,333 | $797.8M | 1.02% |
| Invesco Ltd. | 2,711,224 | $755.4M | 0.97% |
| FRANKLIN RESOURCES INC | 2,510,305 | $699.4M | 0.90% |
| Pictet Asset Management Holding SA | 2,501,585 | $697.0M | 0.89% |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2,293,546 | $639.0M | 0.82% |
Institutional ownership by quarter
Holder changes by quarter
| Quarter | Holders | Ownership | New | Increased | Reduced | Closed |
|---|---|---|---|---|---|---|
| 2026-06-30 | 1,723 | 81.0% | 147 | 620 | 691 | 112 |
| 2026-03-31 | 1,706 | 78.8% | 154 | 648 | 643 | 106 |
| 2025-12-31 | 1,684 | 80.8% | 192 | 582 | 644 | 99 |
| 2025-09-30 | 1,623 | 78.8% | 119 | 630 | 592 | 101 |
| 2025-06-30 | 1,634 | 81.1% | 139 | 617 | 606 | 107 |
| 2025-03-31 | 1,621 | 80.2% | 156 | 565 | 646 | 84 |
| 2024-12-31 | 1,567 | 78.9% | 190 | 559 | 558 | 102 |
| 2024-09-30 | 1,503 | 77.3% | 124 | 525 | 582 | 66 |
| 2024-06-30 | 1,461 | 77.4% | 121 | 550 | 536 | 71 |
| 2024-03-31 | 1,428 | 77.6% | 156 | 465 | 571 | 74 |
| 2023-12-31 | 1,366 | 76.9% | 192 | 445 | 531 | 69 |
| 2023-09-30 | 1,262 | 76.7% | 96 | 490 | 452 | 105 |
Schedule 13D / 13G filers
| Filed | Form | Filer | % of class | Shares |
|---|---|---|---|---|
| 2026-07-16 | SCHEDULE 13G | JPMORGAN CHASE & CO | 5.1% | 14,448,038 |
| 2026-04-29 | SCHEDULE 13G | Vanguard Capital Management | 6.7% | 19,004,742 |
| 2026-03-26 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 |
ETFs with the largest holding
| ETF | Weight in fund | Holding value |
|---|---|---|
| VITSX | 0.09% | $2.2B |
| VSMPX | 0.09% | $2.2B |
| VTSAX | 0.09% | $2.2B |
| VTI | 0.09% | $2.2B |
| VOO | 0.11% | $1.8B |
| VFINX | 0.11% | $1.8B |
Share structure
Income statement
Fiscal years, USD| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Revenue | $12.7B | $14.2B | $15.3B | $15.7B | $16.1B |
| Cost of revenue | $7.5B | $8.8B | $9.1B | $8.9B | $8.9B |
| Gross profit | $5.2B | $5.4B | $6.2B | $6.8B | $7.2B |
| R&D | $186.0M | $190.0M | $192.0M | $207.0M | $0 |
| SG&A | $3.4B | $3.6B | $3.8B | $4.0B | $4.3B |
| Operating income | $1.7B | $1.6B | $2.2B | $2.6B | $2.9B |
| EBITDA | $2.5B | $2.5B | $3.0B | $3.8B | $3.5B |
| Pretax income | $1.4B | $1.3B | $1.8B | $2.6B | $2.5B |
| Income tax | $270.2M | $234.5M | $362.5M | $439.3M | $454.6M |
| Net income | $1.1B | $1.1B | $1.4B | $2.1B | $2.1B |
| EPS, diluted | $3.91 | $3.81 | $4.79 | $7.37 | $7.28 |
| Diluted shares | 289.1M | 286.6M | 286.5M | 286.6M | 285.2M |
Balance sheet
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Cash & short-term investments | $359.9M | $598.6M | $919.5M | $1.3B | $646.2M |
| Receivables | $2.6B | $2.9B | $3.0B | $3.0B | $3.2B |
| Inventory | $1.5B | $1.8B | $1.5B | $1.5B | $1.5B |
| Total current assets | $4.7B | $5.5B | $5.6B | $6.0B | $6.0B |
| PP&E, net | $3.7B | $3.7B | $4.0B | $4.5B | $5.0B |
| Goodwill & intangibles | $12.3B | $11.7B | $11.6B | $11.2B | $12.9B |
| Total assets | $21.2B | $21.5B | $21.8B | $22.4B | $24.7B |
| Accounts payable | $1.4B | $1.7B | $1.6B | $1.8B | $2.1B |
| Total current liabilities | $3.6B | $4.2B | $4.3B | $4.8B | $5.5B |
| Long-term debt | $8.3B | $8.1B | $7.6B | $6.9B | $8.0B |
| Total liabilities | $14.0B | $14.2B | $13.8B | $13.6B | $14.9B |
| Shareholders' equity | $7.3B | $7.3B | $8.1B | $8.8B | $9.8B |
Cash flow statement
Outflows are negative| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Net income | $1.1B | $1.1B | $1.4B | $2.1B | $2.1B |
| Depreciation & amortization | $843.1M | $938.7M | $923.6M | $935.4M | $672.6M |
| Stock-based compensation | $89.5M | $87.8M | $95.1M | $134.8M | $136.6M |
| Change in working capital | $600,000 | −$276.7M | $162.7M | $176.1M | −$206.2M |
| Operating cash flow | $2.1B | $1.8B | $2.4B | $2.8B | $3.0B |
| Capital expenditure | −$643.0M | −$712.8M | −$774.8M | −$994.5M | −$1.0B |
| Free cash flow | $1.4B | $1.1B | $1.6B | $1.8B | $1.9B |
| Investing cash flow | −$4.6B | −$716.8M | −$990.5M | −$433.8M | −$2.7B |
| Net debt issued / repaid | $2.1B | $89.7M | −$501.9M | −$628.5M | $469.6M |
| Buybacks | −$106.6M | −$518.2M | −$13.7M | −$986.5M | −$783.8M |
| Dividends paid | −$566.4M | −$602.8M | −$617.3M | −$664.3M | −$753.6M |
Ratio history
Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Gross margin | 41.0% | 38.2% | 40.3% | 43.5% | 44.5% |
| Operating margin | 13.2% | 11.3% | 14.1% | 16.6% | 17.7% |
| Net margin | 8.9% | 7.7% | 9.0% | 13.4% | 12.9% |
| FCF margin | 11.1% | 7.6% | 10.7% | 11.6% | 11.8% |
| ROE | 16.9% | 15.1% | 18.0% | 25.1% | 22.4% |
| ROIC | 8.5% | 8.5% | 10.8% | 13.7% | 12.6% |
| ROA | 5.7% | 5.1% | 6.3% | 9.6% | 8.8% |
| Debt / equity | 1.27 | 1.25 | 1.09 | 0.95 | 0.97 |
| Interest coverage | 7.8x | 6.0x | 5.9x | 8.6x | 9.2x |
| Current ratio | 1.32 | 1.30 | 1.30 | 1.26 | 1.08 |
| Revenue growth | +8.0% | +11.4% | +8.0% | +2.7% | +2.2% |
| EPS growth | +193.5% | −2.1% | +25.1% | +54.7% | −1.2% |
| P/E at year end | 57.4x | 36.9x | 40.7x | 31.4x | 35.9x |
| EV / EBITDA at year end | 29.2x | 19.1x | 21.0x | 19.1x | 23.9x |
| FCF yield at year end | 2.19% | 2.67% | 2.93% | 2.75% | 2.55% |
| Dividend payout | 50.1% | 55.2% | 45.0% | 31.4% | 36.3% |
Revenue by segment
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|
| Global Water | — | — | — | — | $8.0B |
| Global Industrial | $6.3B | $6.7B | $7.2B | $7.9B | — |
| Global Institutional and Specialty | $4.0B | $4.5B | $5.0B | $5.4B | $6.1B |
| Global Healthcare and Life Sciences | $1.2B | $1.6B | $1.6B | $1.4B | — |
| Other | $1.2B | $1.4B | $1.4B | — | — |
| Global Pest Elimination | — | — | — | $1.2B | $1.2B |
| Global Life Sciences | — | — | — | — | $747.9M |
Revenue by region · FY2025
Street estimates by fiscal year
Next report 2026-10-27 · consensus EPS $2.17 · these are analysts' numbers, not ours| Fiscal year | Revenue (mean) | Revenue range | EPS (mean) | EPS range | Analysts | P/E on mean EPS |
|---|---|---|---|---|---|---|
| 2026 | $17.9B | $17.8B – $18.1B | $8.15 | $8.13 – $8.19 | 14 | 35.4x |
| 2027 | $19.3B | $18.1B – $19.7B | $9.38 | $8.99 – $9.63 | 13 | 30.8x |
| 2028 | $20.4B | $19.8B – $20.9B | $10.71 | $10.23 – $11.38 | 5 | 27.0x |
Reported vs expected, every quarter on file
| Reported | EPS expected | EPS actual | EPS surprise | Revenue expected | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|
| 2026-04-28 | $1.70 | $1.70 | 0.0% | $4.0B | $4.1B | +1.0% |
| 2026-02-10 | $2.07 | $2.08 | +0.5% | $4.2B | $4.2B | +0.1% |
| 2025-10-28 | $2.07 | $2.07 | 0.0% | $4.1B | $4.2B | +1.1% |
| 2025-07-29 | $1.90 | $1.89 | −0.5% | $4.0B | $4.0B | +0.1% |
| 2025-04-29 | $1.50 | $1.50 | 0.0% | $3.7B | $3.7B | −0.0% |
| 2025-02-11 | $1.81 | $1.81 | 0.0% | $4.0B | $4.0B | +0.5% |
| 2024-10-29 | $1.82 | $1.83 | +0.5% | $4.0B | $4.0B | −0.8% |
| 2024-07-30 | $1.67 | $1.68 | +0.6% | $4.0B | $4.0B | −1.2% |
| 2024-04-30 | $1.34 | $1.34 | 0.0% | $3.7B | $3.8B | +0.2% |
| 2024-02-13 | $1.54 | $1.55 | +0.6% | $3.9B | $3.9B | +0.1% |
| 2023-10-31 | $1.52 | $1.54 | +1.3% | $4.0B | $4.0B | −1.2% |
| 2023-08-01 | $1.21 | $1.24 | +2.5% | $3.9B | $3.9B | −0.2% |
| 2023-05-02 | $0.86 | $0.88 | +2.3% | $3.5B | $3.6B | +2.8% |
| 2023-02-14 | $1.25 | $1.27 | +1.6% | $3.7B | $3.7B | −0.9% |
| 2022-11-01 | $1.31 | $1.30 | −0.8% | $3.7B | $3.7B | +0.3% |
| 2022-07-26 | $1.09 | $1.10 | +0.9% | $3.5B | $3.6B | +2.7% |
| 2022-04-26 | $0.82 | $0.82 | 0.0% | $3.2B | $3.3B | +2.4% |
| 2022-02-15 | $1.31 | $1.28 | −2.3% | $3.4B | $3.4B | +0.1% |
| 2021-10-26 | $1.30 | $1.41 | +8.5% | $3.3B | $3.3B | +0.8% |
| 2021-07-27 | $1.21 | $1.22 | +0.8% | $3.3B | $3.2B | −4.1% |
| 2021-04-27 | $0.82 | $0.81 | −1.2% | $2.9B | $2.9B | −0.5% |
| 2021-02-16 | $1.25 | $1.23 | −1.6% | $3.1B | $3.1B | −1.6% |
| 2020-10-27 | $1.09 | $1.15 | +5.5% | $2.9B | $3.0B | +2.7% |
| 2020-07-28 | $0.83 | $0.65 | −21.7% | $3.5B | $2.7B | −23.5% |
Off-exchange (dark pool) volume, weekly
FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)| Week of | Notional | Shares | Trades |
|---|---|---|---|
| 2026-08-31 | $439.4M | 1,564,378 | 62,264 |
| 2026-08-24 | $589.1M | 2,047,758 | 74,757 |
| 2026-08-17 | $754.3M | 2,684,892 | 82,495 |
| 2026-08-10 | $354.7M | 1,266,467 | 55,912 |
| 2026-08-03 | $532.1M | 1,888,844 | 72,685 |
| 2026-07-27 | $682.4M | 2,451,378 | 82,041 |
Short-sale share of off-exchange volume
daily 20-day average| Date | Short share | Short volume | Total volume |
|---|---|---|---|
| 2026-10-15 | 36.8% | 286,188 | 778,521 |
| 2026-10-14 | 28.0% | 130,789 | 467,935 |
| 2026-10-13 | 29.6% | 140,613 | 474,840 |
| 2026-10-12 | 53.6% | 182,971 | 341,666 |
| 2026-10-09 | 52.0% | 167,676 | 322,753 |
| 2026-10-08 | 42.2% | 160,661 | 380,771 |
| 2026-10-07 | 49.9% | 226,484 | 453,911 |
| 2026-10-06 | 41.0% | 195,476 | 476,682 |
| 2026-10-05 | 51.6% | 174,442 | 338,006 |
| 2026-10-02 | 45.5% | 211,886 | 465,765 |
Seasonality
Average return by calendar month| Month | Avg return | Up years | Years |
|---|---|---|---|
| Jan | −0.4% | 45% | 20 |
| Feb | +0.6% | 50% | 20 |
| Mar | +0.8% | 67% | 21 |
| Apr | +3.5% | 65% | 20 |
| May | +1.0% | 60% | 20 |
| Jun | +1.2% | 55% | 20 |
| Jul | +0.5% | 50% | 20 |
| Aug | +1.7% | 60% | 20 |
| Sep | +0.7% | 50% | 20 |
| Oct | −0.4% | 45% | 20 |
| Nov | +3.5% | 75% | 20 |
| Dec | +0.1% | 50% | 20 |
Indicators
as of 2026-10-16Moving averages and bands
level (price vs level)About Ecolab Inc.
Ecolab Inc. provides water, hygiene, and infection prevention solutions and services in the United States and internationally. The company operates through four segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences. The Global Water segment offers water treatment and process applications, and cleaning and sanitizing solutions to manufacturing, food and beverage processing, transportation, chemical, primary metals and mining, power generation, global refining, petrochemical, pulp and paper industries. The Global Institutional & Specialty segment provides cleaning and sanitizing products to the foodservice, healthcare, hospitality, lodging, government, education and retail industries. The Global Pest Elimination segment provides pest elimination services to detect, prevent, and eliminate pests comprising rodents and insects in full-service and quick-service restaurants, food and beverage processors, hotels, grocery operations, and other commercial segments, including education, life sciences, and healthcare. The Global Life Sciences segment provides cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. It offers its products under the Ecolab, Kay, Purolite, and Bioquell brand names. The company sells its products through field sales and corporate account personnel, distributors, and dealers. Ecolab Inc. was founded in 1923 and is headquartered in Saint Paul, Minnesota.
Key executives
| Name | Title | Pay | Born |
|---|---|---|---|
| Christophe Beck | CEO, President & Chairman of the Board | $5.2M | 1968 |
| Darrell R. Brown | Co-Chief Operating Officer of Global Markets | $2.4M | 1964 |
| Scott D. Kirkland | Chief Financial Officer | $2.2M | 1974 |
| Gregory Russell Cook | Co-Chief Operating Officer of Global Businesses | $1.6M | 1969 |
| Margeaux King | Executive Vice President of Human Resources | $1.1M | 1978 |
| Bryce L. Mewhorter | Senior Vice President, Corporate Controller & Principal Accounting Officer | — | 1975 |
| Dan D. LeCloux | Executive VP & Chief Technical Officer | — | — |
| Jandeen Boone | Executive Vice President, General Counsel, Secretary & Interim Chief Compliance Officer | — | 1974 |
Executive pay, latest proxy
| Executive | Year | Salary | Stock awards | Incentive | Total |
|---|---|---|---|---|---|
| Christophe Beck Chairman and Chief Executive Officer | 2025 | $1.4M | $7.2M | $3.4M | $17.4M |
| Darrell R. Brown President and Chief Operating Officer | 2025 | $856,727 | $1.9M | $1.3M | $5.6M |
| Scott D. Kirkland Chief Financial Officer | 2025 | $856,727 | $1.7M | $1.3M | $5.2M |
| Margeaux M. King Executive Vice President, Human Resources | 2025 | $545,769 | $2.7M | $534,054 | $4.7M |
| Gregory B. Cook Executive Vice President and President − Institutional Group | 2025 | $632,100 | $963,623 | $841,721 | $3.4M |
Employees
Dividends
| Ex-date | Amount | Paid |
|---|---|---|
| 2026-09-15 | $0.73 | 2026-10-15 |
| 2026-06-16 | $0.73 | 2026-07-15 |
| 2026-03-17 | $0.73 | 2026-04-15 |
| 2025-12-16 | $0.73 | 2026-01-15 |
| 2025-09-16 | $0.65 | 2025-10-15 |
| 2025-06-17 | $0.65 | 2025-07-15 |
| 2025-03-18 | $0.65 | 2025-04-15 |
| 2024-12-17 | $0.65 | 2025-01-15 |